Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in ...

Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...

BAY43-9006 (Sorafenib) Small-molecule inhibitor BRAF, EGFR ... Immunological checkpoint blockade with anti-CTLA-4 and other monoclonal antibodies targeting costimulatory molecules is a promising ...

This hampers the effects of existing immunotherapies like CTLA-4 and PD-1 inhibitors, which work by mobilizing a person’s own immune system against their cancer. As a result, people with cold ...

Highlights Presentation Details: Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with ...

Presentation Details: Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24 th, 1:39-1:45 p.m. PST (instead of ...